| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Greenwich Lifesciences, Inc. (GLSI) has 1 insider with recent SEC Form 4 filings, including 11 buys and 0 sells. GLSI is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 5.60M | $128.67M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Apr 7, 2025 | Patel Snehal | CEO And CFO | Buy | 3,600 | $9.10 | $32,760.00 | - | |
| Apr 4, 2025 | Patel Snehal | CEO And CFO | Buy | 5,500 | $8.73 | $48,015.00 | - | |
| Jan 10, 2025 | Patel Snehal | CEO And CFO | Buy | 2,500 | $12.51 | $31,275.00 | - | |
| Jan 7, 2025 | Patel Snehal | CEO And CFO | Buy | 2,900 | $13.58 | $39,391.00 | - | |
| Jan 3, 2025 | Patel Snehal | CEO And CFO | Buy | 3,400 | $12.95 | $44,030.00 | - | |
| Jan 2, 2025 | Patel Snehal | CEO And CFO | Buy | 2,000 | $11.97 | $23,940.00 | - | |
| Dec 31, 2024 | Patel Snehal | CEO And CFO | Buy | 2,400 | $11.36 | $27,264.00 | - | |
| Dec 30, 2024 | Patel Snehal | CEO And CFO | Buy | 3,200 | $11.12 | $35,584.00 | - | |
| Nov 21, 2024 | Thompson Jaye | VP Clinical Reg Affairs | Buy | 1,000 | $12.91 | $12,910.00 | +0.4% | |
| Sep 26, 2024 | Patel Snehal | CEO And CFO | Buy | 1,500 | $14.63 | $21,945.00 | - |